Thrive Earlier Detection envisions a future in which blood drawn at an annual physical is used to find early-stage cancer.

Thrive combines cutting-edge liquid biopsy technology with a machine learning engine to find multiple cancer types from a single blood draw — including many cancers that lack effective screening tools such as ovarian, pancreatic, liver cancers and others.

• Industry

  • AI & Machine Learning
  • Biotechnology

• Milestones

  • Lux investment: 2020

• Founders

  • Kenneth W. Kinzler, Ph.D.
  • Nickolas Papadopoulos, Ph.D.
  • Bert Vogelstein, M.D.

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • We are thrilled to be included in @businessinsider's list of biotech companies to watch! We are committed to integr… https://t.co/O6xmhtS6w3@ThriveDetect - 4h
  • Former Senator and Thrive consultant @ByronDorgan talks about cancer screening in today's @MorningConsult, discussi… https://t.co/TFiFj3jLuZ@ThriveDetect - 12:42 PM Aug 11th
  • Take a listen: Thrive co-founder Dr. Bert Vogelstein spoke with @ARKinvest's Simon Barnett to talk about the histor… https://t.co/qjR2dpIAU3@ThriveDetect - 09:46 PM Jul 30th